Phase 3 Trials: Secukinumab for Psoriatic Arthritis & DA-DKP for OA

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 Sep 19;386(9,999):1137–1146. doi: 10.1016/S0140-6736(15)61134-5.
Ampio Pharmaceuticals Inc. News release: Ampio receives special protocol assessment (SPA) from the FDA and commences second phase III pivotal trial of Ampion. 2015 Sep 22.
Ampio Pharmaceuticals Inc. About Ampion for the treatment of osteoarthritis of the knee. 2015.

A posthoc analysis confirms patients with active psoriatic arthritis (PsA) taking secukinumab experience improvement in all signs and symptoms of PsA as measured by the GRAPPA-OMERACT disease activity core domains.

PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…

In a four-year study, patients with active psoriatic arthritis (PsA) experienced sustained improvement in PsA signs and symptoms on secukinumab…

An overview of the research to date and the ways in which such evidence can be used to guide the treatment of patients was presented at the 2019 ACR/ARP Annual Meeting in a session titled Optimizing Outcomes in Psoriatic Arthritis: A Domain-Based Strategy. In the years since this presentation, additional research has helped supply greater…

Secukinumab Effective Across the Spectrum of Psoriatic Arthritis

Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022

Psoriatic Arthritis Patients Show Long-Term, Sustained Improvement with Secukinumab

The Latest Psoriatic Arthritis Management Insights

Related Articles